{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=17",
    "query": {
      "intervention": "Daily dosing",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 3693,
    "total_pages": 370,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daily+dosing&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T19:57:22.784Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06628128",
      "title": "A Long-Term Study of JNT-517 in Participants With Phenylketonuria",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Phenylketonuria (PKU)"
      ],
      "interventions": [
        {
          "name": "JNT-517",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2025-08-11",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 8,
      "location_summary": "Gainesville, Florida • Tampa, Florida • Portland, Oregon + 4 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06628128"
    },
    {
      "nct_id": "NCT04910919",
      "title": "Here's the Buzz: Evaluating Pediatric Post Op Pain and Nausea Following Tonsillectomy Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tonsillectomy"
      ],
      "interventions": [
        {
          "name": "Honey",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-03",
      "completion_date": "2022-07",
      "has_results": false,
      "last_update_posted_date": "2022-07-07",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04910919"
    },
    {
      "nct_id": "NCT02714036",
      "title": "A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ibudilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediciNova",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2016-05-06",
      "completion_date": "2020-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Patchogue, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Patchogue",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02714036"
    },
    {
      "nct_id": "NCT04245371",
      "title": "Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Carpal Tunnel Syndrome"
      ],
      "interventions": [
        {
          "name": "Lidocaine 1.8%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Papakonstantinou, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2020-02-24",
      "completion_date": "2023-05-07",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 1,
      "location_summary": "Rochester Hills, Michigan",
      "locations": [
        {
          "city": "Rochester Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04245371"
    },
    {
      "nct_id": "NCT00654875",
      "title": "Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Aliskiren",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Aliskiren",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2008-03",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2011-06-28",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 1,
      "location_summary": "Zanesville, Ohio",
      "locations": [
        {
          "city": "Zanesville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00654875"
    },
    {
      "nct_id": "NCT07892664",
      "title": "Reducing Arterial Inflammation Using Eplerenone and Statins in HIV",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV (Human Immunodeficiency Virus)",
        "Cardiovascular Diseases (CVD)",
        "Arterial Inflammation",
        "Heart Disease"
      ],
      "interventions": [
        {
          "name": "Eplerenone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 124,
      "start_date": "2027-03-01",
      "completion_date": "2031-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07892664"
    },
    {
      "nct_id": "NCT01340651",
      "title": "Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2011-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-03-10",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Winter Park, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01340651"
    },
    {
      "nct_id": "NCT01434602",
      "title": "Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumor",
        "Glioblastoma",
        "Anaplastic Glioma"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2012-10-02",
      "completion_date": "2021-07-13",
      "has_results": true,
      "last_update_posted_date": "2022-06-01",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434602"
    },
    {
      "nct_id": "NCT02163694",
      "title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Veliparib Placebo",
          "type": "DRUG"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 513,
      "start_date": "2014-04-08",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2025-02-19",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 56,
      "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163694"
    },
    {
      "nct_id": "NCT05207865",
      "title": "Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine",
        "Episodic Migraine",
        "Phonophobia",
        "Photophobia"
      ],
      "interventions": [
        {
          "name": "Rimegepant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 441,
      "start_date": "2022-03-15",
      "completion_date": "2024-07-02",
      "has_results": true,
      "last_update_posted_date": "2025-09-03",
      "last_synced_at": "2026-10-30T19:57:22.784Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Hawthorne, California • North Hollywood, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hawthorne",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05207865"
    }
  ]
}